Cargando…
Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework
Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for t...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138948/ https://www.ncbi.nlm.nih.gov/pubmed/30238023 http://dx.doi.org/10.1016/j.ynstr.2018.08.003 |
_version_ | 1783355433838182400 |
---|---|
author | Greenwald, Mark K. |
author_facet | Greenwald, Mark K. |
author_sort | Greenwald, Mark K. |
collection | PubMed |
description | Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for the most commonly abused substances). I evaluate neuropharmacological mechanisms in experimental models of drug-maintenance and relapse, which translate more readily to individuals presenting for treatment (who have initiated and progressed). An affective/motivational systems model (three dimensions: valence, arousal, control) is mapped onto a systems biology of addiction approach for addressing this problem. Based on quality of evidence to date, promising first-tier neurochemical receptor targets include: noradrenergic (α1 and β antagonist, α2 agonist), kappa-opioid antagonist, nociceptin antagonist, orexin-1 antagonist, and endocannabinoid modulation (e.g., cannabidiol, FAAH inhibition); second-tier candidates may include corticotropin releasing factor-1 antagonists, serotonergic agents (e.g., 5-HT reuptake inhibitors, 5-HT3 antagonists), glutamatergic agents (e.g., mGluR2/3 agonist/positive allosteric modulator, mGluR5 antagonist/negative allosteric modulator), GABA-promoters (e.g., pregabalin, tiagabine), vasopressin 1b antagonist, NK-1 antagonist, and PPAR-γ agonist (e.g., pioglitazone). To address affective/motivational mechanisms of stress-related substance use, it may be advisable to combine agents with actions at complementary targets for greater efficacy but systematic studies are lacking except for interactions with the noradrenergic system. I note clinically-relevant factors that could mediate/moderate the efficacy of anti-stress therapeutics and identify research gaps that should be pursued. Finally, progress in developing anti-stress medications will depend on use of reliable CNS biomarkers to validate exposure-response relationships. |
format | Online Article Text |
id | pubmed-6138948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-61389482018-09-20 Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework Greenwald, Mark K. Neurobiol Stress Article Stress-related substance use is a major challenge for treating substance use disorders. This selective review focuses on emerging pharmacotherapies with potential for reducing stress-potentiated seeking and consumption of nicotine, alcohol, marijuana, cocaine, and opioids (i.e., key phenotypes for the most commonly abused substances). I evaluate neuropharmacological mechanisms in experimental models of drug-maintenance and relapse, which translate more readily to individuals presenting for treatment (who have initiated and progressed). An affective/motivational systems model (three dimensions: valence, arousal, control) is mapped onto a systems biology of addiction approach for addressing this problem. Based on quality of evidence to date, promising first-tier neurochemical receptor targets include: noradrenergic (α1 and β antagonist, α2 agonist), kappa-opioid antagonist, nociceptin antagonist, orexin-1 antagonist, and endocannabinoid modulation (e.g., cannabidiol, FAAH inhibition); second-tier candidates may include corticotropin releasing factor-1 antagonists, serotonergic agents (e.g., 5-HT reuptake inhibitors, 5-HT3 antagonists), glutamatergic agents (e.g., mGluR2/3 agonist/positive allosteric modulator, mGluR5 antagonist/negative allosteric modulator), GABA-promoters (e.g., pregabalin, tiagabine), vasopressin 1b antagonist, NK-1 antagonist, and PPAR-γ agonist (e.g., pioglitazone). To address affective/motivational mechanisms of stress-related substance use, it may be advisable to combine agents with actions at complementary targets for greater efficacy but systematic studies are lacking except for interactions with the noradrenergic system. I note clinically-relevant factors that could mediate/moderate the efficacy of anti-stress therapeutics and identify research gaps that should be pursued. Finally, progress in developing anti-stress medications will depend on use of reliable CNS biomarkers to validate exposure-response relationships. Elsevier 2018-08-11 /pmc/articles/PMC6138948/ /pubmed/30238023 http://dx.doi.org/10.1016/j.ynstr.2018.08.003 Text en © 2018 The Author http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Greenwald, Mark K. Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework |
title | Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework |
title_full | Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework |
title_fullStr | Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework |
title_full_unstemmed | Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework |
title_short | Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework |
title_sort | anti-stress neuropharmacological mechanisms and targets for addiction treatment: a translational framework |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138948/ https://www.ncbi.nlm.nih.gov/pubmed/30238023 http://dx.doi.org/10.1016/j.ynstr.2018.08.003 |
work_keys_str_mv | AT greenwaldmarkk antistressneuropharmacologicalmechanismsandtargetsforaddictiontreatmentatranslationalframework |